Table 1 Chimeric antigen receptor T-cell products developed in China
Product name | Generic name | Manufacturer | Target | Antigen-recognition domain | Approved indication | Approved by | Time of approval | Relevant studies |
|---|---|---|---|---|---|---|---|---|
Zevor-cel | Zevorcabtagene Autoleucel | CARsgen Therapeutics, Shanghai, China | BCMA | a fully human BCMA-specific scFv (25C2) | Adult r/r MM progressed after at least 3 lines of systemic therapy, including a PI and an IMiD | NMPA | 2024-02-23 | [4] |
CNCT19 (Inati-cel) | Inaticabtagene Autoleucel | Juventas Cell Therapy, Tianjin, China | CD19 | a unique CD19 scFv derived from CD19 monoclonal antibody (HI19a) | Adult r/r B-ALL | NMPA | 2023-11-07 | [5] |
Fucaso (Eque-cel) | Equecabtagene Autoleucel | IASO Bio, Nanjing, China | BCMA | a fully human scFv | Adult r/r MM progressed after at least 3 lines of systemic therapy, including a PI and an IMiD | NMPA | 2023-06-30 | [6] |
Carvykti (Cilta-cel) | Ciltacabtagene Autoleucel | Janssen, New Jersey, US; Legend Biotech, Nanjing, China | BCMA | two llama (camelid) heavy chains (VH) as a scFv | Adult r/r MM after at least 4 lines of therapy, including a PI, an IMiD, and an anti-CD38 monoclonal antibody | FDA | 2022-02-28 | [7] |
Relma-cel | Relmacabtagene Autoleucel | JW Therapeutics, Shanghai, China | CD19 | scFv derived from a murine CD19-specific mAb (FMC63) | Adult r/r LBCL after at least 2 lines of systemic therapy | NMPA | 2021-09-01 | |
Yescarta (Axi-cel) | Axicabtagene Ciloleucel | Fosun Kite Biotechnology, Shanghai, China | CD19 | scFv derived from a murine CD19-specific mAb (FMC63) | Adult r/r LBCL after at least 2 lines of systemic therapy; adult LBCL fail to respond to first-line immunochemotherapy or relapse within 12 months after first-line immunochemotherapy | NMPA | 2021-06-22 |